Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia

European Journal of Haematology

Volumn 88, Issue 4, 2012, Pages 321-328

  Chang, Hung ^a   Kuo, Ming Chung ^a   Shih, Lee Yung ^a   Dunn, Po ^a   Wang, Po Nan ^a   Wu, Jin Hou ^a   Lin, Tung Liang ^a   Hung, Yu Shin ^a   Tang, Tzung Chih ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Acute promyelocytic leukemia; Bleeding; Disseminated intravascular coagulation; Fibrinogen; Prothrombin time

Indexed keywords

ARSENIC TRIOXIDE; FIBRINOGEN; FRESH FROZEN PLASMA; RETINOIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LABORATORY TEST; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; DATABASES, FACTUAL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOGEN; HEMORRHAGE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; PROTHROMBIN TIME; RISK;

EID: 84862795595     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01747.x     Document Type: Article

References (22)

1. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010;125(Suppl 2):S51-4.
2. Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007;33:330-8.
3. Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P, Farcet JP, Rodet M, Duedari N, Imbert M. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985;55:18-25.
4. Di BE, Avvisati G, Castaman G, Luce VM, De SV, Rodeghiero F, Mandelli F. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000;108:689-95.
5. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248-54.
6. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007;78:213-9.
7. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008;111:3395-402. Epub 2008 Jan 14.
8. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005;116:109-14.
9. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33. Epub 2009 Feb 12.
10. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006;135:450-74. Epub 2006 Oct 10.
11. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001;106:43-51.
14. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012;156:24-36.
15. Visani G, Gugliotta L, Tosi P, et al. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. Eur J Haematol 2000;64:139-44.
16. Zhao W, Wang H, Wang X, Wu F, Guo W, Qu B, Shen Z, Wang Z. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res 2001;102:197-204.
17. Kim DY, Lee JH, Kim SD, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res 2010;35:152-8.
18. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989;3:23-8.
19. Chen CY, Tai CH, Tsay W, Chen PY, Tien HF. Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Ann Oncol 2009;20:1100-4.
20. Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in PML. Am J Hematol 2006;81:720.
21. Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004;72:455-6.
22. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91.